-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
mTOR is a serine-threonine kinase and a key component of a non-overlapping multi-subunit complex with two downstream targets (mTOR complex 1 and 2)
This is a multi-center, single-group prospective phase II trial to evaluate the therapeutic activity of everolimus, an oral inhibitor of mTORC1, in patients with advanced solid tumors with TSC1/TSC2 or MTOR mutations
Patients with advanced solid tumors carrying TSC1/TSC2 inactivating mutations or MTOR activating mutations were recruited and treated with 10 mg everolimus every day until the disease progressed or intolerable toxicity appeared
The type of cancer in the test patient
The type of cancer in the test patientFrom November 2015 to October 2018, a total of 30 patients were recruited, of which 13 had TSC1 mutations, 15 had TSC2 mutations, 1 had both TSC1 and TSC2 mutations, and 1 had MTOR mutations
Treatment remission
Treatment remissionThe median progression-free survival was 2.
The median progression-free survival was 2.
Original source:
Original source:Elio Adib, Katarzyna Klonowska, et al.
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
in this message